Incyte Corp(INCY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low99.66
Day High99.66
Open:99.66
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
StockStory
2 Growth Stocks to Add to Your Roster and 1 We Avoid
AVAV
Tipranks
Analysts Conflicted on These Healthcare Names: Simulations Plus (SLP), Incyte (INCY) and Glaukos (GKOS)
Tipranks
Stifel Nicolaus Sticks to Its Buy Rating for Incyte (INCY)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Incyte (INCY), Pharvaris (PHVS)
Tipranks
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)
Tipranks
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Rhythm Pharmaceuticals (RYTM) and Damora Therapeutics (DMRA)
Tipranks
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX)
Tipranks
Incyte’s POD1UM-204 Endometrial Cancer Study Wraps Up, Setting the Stage for Key Retifanlimab Data
Tipranks
Analysts Offer Insights on Healthcare Companies: MaxCyte (MXCT) and Incyte (INCY)
Tipranks
Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Incyte (INCY) and Incannex Healthcare Limited Sponsored ADR (IXHL)
Tipranks
Incyte Shareholders Back Board, Pay and Auditor Choices
StockStory
Why Incyte (INCY) Stock Is Up Today
INCY
Tipranks
Analysts Offer Insights on Healthcare Companies: Artivion (AORT), Incyte (INCY) and ClearPoint Neuro (CLPT)
Tipranks
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Nuvalent (NUVL) and Viking Therapeutics (VKTX)
Tipranks
Analysts’ Top Healthcare Picks: Incyte (INCY), Zevra Therapeutics (ZVRA)
Tipranks
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Erasca (ERAS) and Incyte (INCY)
Tipranks
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and IDEAYA Biosciences (IDYA)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and Option Care Health (OPCH)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dexcom (DXCM), Revolution Medicines (RVMD) and Incyte (INCY)

Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.